Annexon (ANNX) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Annexon (ANNX) over the past year, gaining 81.3% versus a gain of 27.0%. Over five years, SLN leads with a -56.4% price change compared with -81.8% for ANNX. Annexon is the larger company by market cap ($758.3 million vs $591.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | SLN |
|---|---|---|
| Share price | $4.00 | $9.52 |
| Market cap | $758.32M | $591.71M |
| 1-day change | -0.25% | -3.05% |
| YTD return | -20.32% | +56.58% |
| 1-year return | +26.98% | +81.33% |
| 5-year return | -81.82% | -56.37% |
| EPS (TTM) | $-1.13 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $17.58 |
| 52-week low | $2.54 | $4.19 |
| Distance from 52-week high | -44.29% | -45.84% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +285.75% | +246.64% |
| Average volume | 3.11M | 1.12M |
| Shares outstanding | 189.58M | 62.15M |
| Employees | 92 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed ANNX by 54.3 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
ANNX vs SLN FAQ
Which is bigger, Annexon or Silence Therapeutics Plc American Depository Share?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $591.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, ANNX or SLN?
SLN returned +81.33% over the past 12 months, compared with +26.98% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.